Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab

Abstract

In the current real-world study, the positive anaphylaxis signals related to omalizumab, benralizumab, reslizumab, and mepolizumab suggested the need for the close monitoring of patients after drug use, and dupilumab showed a negative signal for anaphylaxis.